Boston Scientific Corp (BSX)vsStandard Biotools Inc (LAB)
BSX
Boston Scientific Corp
$44.23
-2.06%
HEALTHCARE · Cap: $60.84B
LAB
Standard Biotools Inc
$0.65
+1.31%
HEALTHCARE · Cap: $243.19M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 24856% more annual revenue ($21.07B vs $84.43M). LAB leads profitability with a 157.6% profit margin vs 16.6%. BSX earns a higher WallStSmart Score of 62/100 (C+).
BSX
Buy62
out of 100
Grade: C+
LAB
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-9.2%
Fair Value
$39.15
Current Price
$44.23
$5.08 premium
Margin of Safety
+89.2%
Fair Value
$11.06
Current Price
$0.65
$10.41 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.2%
Reasonable price relative to book value
Keeps 158 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Areas to Watch
1.4% revenue growth
Distress zone — elevated risk
Earnings declined 21.5%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -16.8% — below average capital efficiency
Revenue declined 0.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 16.6% and operating margin at 20.2%. PEG of 0.63 suggests the stock is reasonably priced for its growth.
Bull Case : LAB
The strongest argument for LAB centers on Price/Book, Profit Margin, Debt/Equity. Profitability is solid with margins at 157.6% and operating margin at -41.7%.
Bear Case : BSX
The primary concerns for BSX are Revenue Growth, Altman Z-Score, EPS Growth.
Bear Case : LAB
The primary concerns for LAB are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
BSX profiles as a value stock while LAB is a declining play — different risk/reward profiles.
LAB carries more volatility with a beta of 1.51 — expect wider price swings.
BSX is growing revenue faster at 1.4% — sustainability is the question.
BSX generates stronger free cash flow (868M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (62/100 vs 42/100), backed by strong 16.6% margins. LAB offers better value entry with a 89.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Standard Biotools Inc
HEALTHCARE · MEDICAL DEVICES · USA
Standard Biotools Inc. (LAB) is a pioneering biotechnology company dedicated to enhancing genomic analysis and biological research through cutting-edge tools and technologies. The firm's focus on developing high-performance products for laboratories in genomics and proteomics is aimed at improving research precision and operational efficiency. Utilizing proprietary platforms, Standard Biotools accelerates scientific discoveries, reinforcing its position as a leader in the dynamic biotechnology landscape. With a commitment to meeting the growing demand for innovative analytical solutions, LAB is strategically positioned to facilitate significant advancements within the life sciences sector.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?